🔴 Novavax is trading 7.18% down with no identified company-specific catalyst

Novavax is trading 7.18% down at $11.90 on October 16, based on the live price provided; no reliable report identifies a company-specific catalyst.

• A positive Sanofi partnership report describes a $1.2 billion agreement but does not connect it to the decline.
• Biotech is up 2.20%, so the sector trend does not explain the move; available market context does not establish a direct broad-market cause.